High-throughput human immunodeficiency virus type 1 (HIV-1) full replication assay that includes HIV-1 Vif as an antiviral target

Antimicrobial Agents and Chemotherapy

Volumn 49, Issue 9, 2005, Pages 3833-3841

  Cao, Joan ^a   Isaacson, Jason ^a   Patick, Amy K ^a   Blair, Wade S ^a  

^a PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; AURINTRICARBOXYLIC ACID; DELAVIRDINE; DIDANOSINE; EFAVIRENZ; INDINAVIR; LAMIVUDINE; NELFINAVIR; NEVIRAPINE; SAQUINAVIR; STAVUDINE; VIF PROTEIN; ZIDOVUDINE;

ANTIVIRAL ACTIVITY; ARTICLE; ASSAY; DRUG TARGETING; EVALUATION; HIGH THROUGHPUT SCREENING; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; NONHUMAN; PRIORITY JOURNAL; T LYMPHOCYTE; VIRUS GENE; VIRUS REPLICATION; VIRUS STRAIN;

ANTIVIRAL AGENTS; DRUG EVALUATION, PRECLINICAL; GENE PRODUCTS, VIF; HELA CELLS; HIV CORE PROTEIN P24; HIV-1; HUMANS; LIKELIHOOD FUNCTIONS; PLASMIDS; VIRUS REPLICATION;

EID: 24144468961     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.49.9.3833-3841.2005     Document Type: Article

References (44)

1. Adelson, M. E., A. L. Pacchia, M. Kaul, R. F. Kando, Y. Ron, S. W. Peltz, and J. P. Dougherty. 2003. Toward the development of a virus-cell-based assay for the discovery of novel compounds against human immunodeficiency virus type 1. Antimicrob. Agents Chemother. 47:501-508.
2. Billich, A. 2003. S-1360 Shionogi-GlaxoSmithKline. Curr. Opin. Investig. Drugs 4:206-209.
3. Blair, W. S., M. Deshpande, H. Fang, P. F. Lin, T. P. Spicer, O. B. Wallace, H. Wang, Wang, T. Z. Zhang, and K. P. Yeung. October 2002. Antiviral indoleoxoacetyl piperizine derivatives. U.S. patent 6469006.
4. Blair, W. S., J. S. Isaacson, X. Li, J. Q. Cao, Q. Peng, G. F. Z. Kong, and A. K. Patick. 2005. A novel HIV-1 antiviral high throughput screening approach for the discovery of HIV-1 inhibitors. Antivir. Res. 65:107-117.
5. Blair, W. S., and T. P. Spicer. January 2003. Reporter viruses and their use in assaying anti-viral compounds. U.S. patent 0013078 A1.
6. Boyd, M. R. 1988. Strategies for the identification of new agents for the treatment of AIDS: a national program to facilitate the discovery and pre-clinical development of new drug candidates for clinical evaluation, p. 305-317. In V. T. DeVita, S. Hellman and S. A. Rosenberg (ed.), AIDS etiology, diagnosis, treatment and prevention. Lippincott, Philadelphia, Pa.
7. Chen, B. K., K. Saksela, R. Andino, and D. Baltimore. 1994. Distinct modes of human immunodeficiency virus type 1 proviral latency revealed by super-infection of nonproductively infected cell lines with recombinant luciferase-encoding viruses. J. Virol. 68:654-660.
8. Conticello, S. G., R. S. Harris, and M. S. Neuberger. 2003. The Vif protein of HIV triggers degradation of the human antiretroviral DNA deaminase APOBEC3G. Curr. Biol. 13:2009-2013.
9. Dorsky, D. I., and R. D. Harrington. 1999. An indicator cell assay for T-cell tropic, macrophage-tropic, and primary isolates of HIV-1 based on green fluorescent protein. J. Acquir. Immune. Defic. Syndr. 22:213-220.
10. Fätkenheuer, G., A. L. Pozniak, M. Johnson, M. A. Plettenberg, S. Staszewski, I. M. Hoepelman, M. Saag, F. Goebel, J. Rockstroh, B. Dezube, T. M. Jenkins, C. Medhurst, J. F. Sullivan, C. Ridgway, S. Abel, M. Youle, and E. van der Ryst. 2004. Evaluation of dosing frequency and food effect on viral load reduction during short-term monotherapy with UK-427,857 a novel CCR5 antagonist. Fifteenth Int. AIDS Conf., abstr. TuPeB4489.
11. Fujioka, T., Y. Kashiwada, R. E. Kilkuskie, L. M. Cosentino, L. M. Ballas, J. B. Jiang, W. P. Janzen, I. S. Chen, and K. H. Lee. 1994. Anti-AIDS agents. 11. Betulinic acid and platanic acid as anti-HIV principles from Syzigium claviflorum, and the anti-HIV activity of structurally related triterpenoids. J. Nat. Prod. 57:243-247.
12. + T lymphocytes. J. Virol. 66:6489-6495.
13. Gulakowski, R. J., J. B. McMahon, P. G. Staley, R. A. Moran, and M. R. Boyd. 1991. A semiautomated multiparameter approach for anti-HIV drug screening. J. Virol. Methods 33:87-100.
14. Hanna, G., J. Lalezari, J. Hellinger, D. Wohl, T. Masterson, W. Fiske, J. Kadow, P. Lin, M. Giordano, R. Colonno, and D. Grasela. 2004. Antiviral activity, safety, and tolerability of a novel, oral small-molecule HIV-1 attachment inhibitor, BMS-488043, in HIV-1-infected subjects. Eleventh Conf. Retrovir. Opportunistic Infect., abstr. 141.
15. Harris, R. S., K. N. Bishop, A. M. Sheehy, H. M. Craig, S. K. Peterson-Mahrt, I. N. Watt, M. S. Neuberger, and M. H. Malim. 2003. DNA deamination mediates innate immunity to retroviral infection. Cell 113:803-809.
16. Horton, R. M., Z. Cai, S. N. Ho, and L. R. Pease. 1990. Gene splicing by overlap extension: tailor-made genes using the polymerase chain reaction. BioTechniques 8:528-535.
17. Johnson, V. A., and R. E. Barrington. 1990. Infectivity assay, p. 71-76. In A. Aldovini and B. D. Walker (ed.), Techniques in HIV research. Stockton Press, New York, N.Y.
18. Kao, S., M. A. Khan, E. Miyagi, R. Plishka, A. Buckler-White, and K. Strebel. 2003. The human immunodeficiency virus type 1 Vif protein reduces intracellular expression and inhibits packaging of APOBEC3G (CEM 15), a cellular inhibitor of virus infectivity. J. Virol. 77:11398-11407.
19. Kashiwada, Y., F. Hashimoto, L. M. Cosentino, C. H. Chen, P. E. Garrett, and K. H. Lee. 1996. Betulinic acid and dihydrobetulinic acid derivatives as potent anti-HIV agents. J. Med. Chem. 39:1016-1017.
20. Kimpton, J., and M. Emerman. 1992. Detection of replication-competent and pseudotyped human immunodeficiency virus with a sensitive cell line on the basis of activation of an integrated beta-galactosidase gene. J. Virol. 66:2232-2239.
21. Lin, P. F., W. Blair, T. Wang, T. Spicer, Q. Guo, N. Zhou, Y. F. Gong, H. G. Wang, R. Rose, G. Yamanaka, B. Robinson, Li, C. B., R. Fridell, C. Deminie, G. Demers, Z. Yang, L. Zadjura, N. Meanwell, and R. Colonno. 2003. A small molecule HIV-1 inhibitor that targets the HIV-1 envelope and inhibits CD4 receptor binding. Proc. Natl. Acad. Sci. USA 100:11013-11018.
22. Little, S. J., S. Holte, J.-P. Routy, E. S. Daar, M. Markowitz, A. C. Collier, R. A. Koup, J. W. Mellors, E. Connick, B. Conway, M. Kilby, L. Wang, J. M. Whitcomh, N. S. Hellmann, and D. D. Richman. 2002. Antiretroviral-drug resistance among patients recently infected with HIV. N. Engl. J. Med. 347:385-394.
23. Mangeat, B., P. Turelli, G. Caron, M. Friedli, L. Perrin, and D. Trono. 2003. Broad antiretroviral defense by human APOBEC3G through lethal editing of nascent reverse transcripts. Nature 424:99-103.
24. Mariani, R., D. Chen, B. Schrofelbauer, F. Navarro, R. Konig, B. Bollman, C. Munk, H. Nymark-McMahon, and N. R. Landau. 2003. Species-specific exclusion of APOBEC3G from HIV-1 virions by Vif. Cell 114:21-31.
25. Marin, M., K. M. Rose, S. L. Kozak, and D. Kabat. 2003. HIV-1 Vif protein binds the editing enzyme APOBEC3G and induces its degradation. Nat. Med. 9:1398-1403.
26. Mehle, A., B. Strack, P. Ancuta, C. Zhang, M. McPike, and D. Gabuzda. 2004. Vif overcomes the innate antiviral activity of APOBEC3G by promoting its degradation in the ubiquitin-proteasome pathway. J. Biol. Chem. 279:7792-7798.
27. Miyake, H., Y. Iizawa, and M. Baba. 2003. Novel reporter T-cell line highly susceptible to both CCR5- and CXCR4-using human immunodeficiency virus type 1 and its application to drug susceptibility tests. J. Clin. Microbiol. 41:2515-2521.
28. Navarro, F., and N. R. Landau. 2004. Recent insights into HIV-1 Vif. Curr. Opin. Immunol. 16:477-482.
29. Page, K. A., T. Liegler, and M. B. Feinberg. 1997. Use of a green fluorescent protein as a marker for human immunodeficiency virus type 1 infection. AIDS Res. Hum. Retrovir. 13:1077-1081.
30. Pais, G. C. G., and T. R. Burke. 2002. Novel aryl diketo-containing inhibitors of HIV-1 integrase. Drugs Future 27:1101-1111.
31. Petropoulos, C. J., N. T. Parkin, K. L. Limoli, Y. S. Lie, T. Wrin, W. Huang, H. Tian, D. Smith, G. A. Winslow, D. J. Capon, and J. W. Whitcomb. 2000. A novel phenotypic drug susceptibility assay for human immunodeficiency virus type 1. Antimicrob. Agents Chemother. 44:920-928.
32. Pirounaki, M., N. A. Heyden, M, Arens, and L. Ratner. 2000. Rapid phenotypic drug susceptibility assay for HIV-1 with a CCR5 expressing indicator cell line. J. Virol. Methods 85:151-161.
33. Sheehy, A. M., N. C. Gaddis, J. D. Choi, and M. H. Malim. 2002. Isolation of a human gene that inhibits HIV-1 infection and is suppressed by the viral Vif protein. Nature 418:646-650.
34. Sheehy, A. M., N. C. Gaddis, and M. H. Malim. 2003. The antiretroviral enzyme APOBEC3G is degraded by the proteasome in response to HIV-1 Vif. Nat. Med. 9:1404-1407.
35. Simon, J. H., D. L. Miller, R. A. Fouchier, M. A. Soares, K. W. Peden, and M. H. Malim. 1998. The regulation of primate immunodeficiency virus infectivity by Vif is cell species restricted: a role for Vif in determining virus host range and cross-species transmission. EMBO J. 17:1259-1267.
36. Spenlehauer, C., C. A. Gordon, A. Trkola, and J. P. Moore. 2001. A luciferase-reporter gene-expressing T-cell line facilitates neutralization and drug-sensitivity assays that use either R5 or X4 strains of human immunodeficiency virus type 1. Virology 280:292-300.
37. Stopak, K., C. de Noronha, W. Yonemoto, and W. C. Greene. 2003. HIV-1 Vif blocks the antiviral activity of APOBEC3G by impairing both its translation and intracellular stability. Mol. Cell 12:591-601.
38. Wang, T., Z. Zhang, O. B. Wallace, M. Deshpande, H. Fang, Z. Yang, L. M. Zadjura, D. L. Tweedie, S. Huang, F. Zhao, S. Ranadive, B. S. Robinson, Y.-F. Gong, K. Ricarrdi, T. P. Spicer, C. Deminie, R. Rose, H. Wang, W. S. Blair, P.-Y. Shi, P.-F. Lin, R. J. Colonno, and N. A. Meanwell. 2003. Discovery of 4-benzoyl-1-[(4-methoxyl-1H-pyrrolo[2,3-b]pyridine-3-yl)oxoacetyl]-2-(R) -methylpiperazine (BMS-378806): a novel HIV-1 attachment inhibitor that interferes with CD4-gp120 interactions. J. Med. Chem. 46:4236-4239.
39. Weislow, O. S., R. Kiser, D. L. Fine, J. Bader, R. H. Shoemaker, and M. R. Boyd. 1989. New soluble-formazan assay for HIV-1 cytopathic effects: application to high-flux screening of synthetic and natural products for AIDS-antiviral activity. J. Natl. Cancer Inst. 81:577-586.
40. Wild, C., N. Kilgore, M. Reddick, Li, F., K. Salzwedel, C. Matallana, G. Allaway, and D. Martin. 2003. PA-457 is a small molecule inhibitor of HIV-1 budding/maturation that potently inhibits replication of virus isolates resistant to all classes of approved drugs. Tenth Conf. Retrovir. Opportunistic Infect., abstr. 14.
41. Yeni, P. G., S. M. Hammer, C. C. J. Carpenter, D. A. Cooper, M. A. Fischl, J. M. Gatell, B. G. Gazzard, M. S. Hirsch, D. M. Jacobsen, D. A. Katzenstein, J. S. G. Montaner, D. D. Richman, M. S. Saag, M. S. Schechter, R. T. Schooley, M. A. Thompson, S. Vella, and P. A. Volberding. 2002. Antiretroviral treatment for adult HIV infection in 2002. Updated recommendations of the International AIDS Society-USA Panel. JAMA 288:222-235.
42. Yu, X., Yu, Y., B. Liu, K. Luo, W. Kong, P. Mao, and X. F. Yu. 2003. Induction of APOBEC3G ubiquitination and degradation by an HIV-1 Vif-Cul5-SCF complex. Science 302:1056-1060.
43. Zhang, H., B. Yang, R. J. Pomerantz, C. Zhang, S. C. Arunachalam, and L. Gao. 2003. The cytidine deaminase CEM15 induces hypermutation in newly synthesized HIV-1 DNA. Nature 424:94-98.
44. Zhang J.-H., T. D. Y. Chung, and K. R. Oldenburg. 1999. A simple statistical parameter for use in evaluation and validation of high throughput screening assays. J. Biomol. Screen 4:67-73.